ONCAlert | Upfront Therapy for mRCC

MPNs VIEW MORE >>

In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, discussed interim results from a phase II study of luspatercept as a treatment of anemia in patients with myelofibrosis, which he presented at the 2019 Annual Society of Hematology Annual Meeting.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.